Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of January 2025, with a specific reporting date of January 13, 2025. The document serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon operates as a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes and Transactions
The filing details two identical share transactions executed on January 10, 2025, on the London Stock Exchange (XLON) under the Company's Share Reward Plan:
- Adrian Morris (General Counsel): Acquired 33 Partnership Shares at a price of £3.7738 per share and received 33 Matching Shares at no cost. Total aggregated volume: 66 shares.
- Tamara Rogers (Chief Marketing Officer): Acquired 33 Partnership Shares at a price of £3.7738 per share and received 33 Matching Shares at no cost. Total aggregated volume: 66 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the disclosure of the specific PDMR transactions listed above.
Investor Verification Checklist
- Verify the total number of shares held by Adrian Morris and Tamara Rogers post-transaction against previous filings.
- Confirm the terms of the Company's Share Reward Plan regarding the matching share mechanism.
- Review the market price of Haleon ordinary shares (GB00BMX86B70) on January 10, 2025, to contextualize the transaction price of £3.7738.